Merck News

Health

Personalized mRNA Vaccine Cuts Melanoma Recurrence or Death Risk 42% in Phase 3 Trial

MADRID - A personalized mRNA cancer vaccine developed by Moderna and Merck reduced the risk of melanoma returning or cau...